Overview

A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a study of safety, tolerability, pharmacokinetics and pharmacodynamics of AM1030-CREAM in patients with Atopic Dermatitis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AnaMar AB
Collaborator:
Covance